AU2001270413A1 - Improved liposomal camptothecins and uses thereof - Google Patents

Improved liposomal camptothecins and uses thereof

Info

Publication number
AU2001270413A1
AU2001270413A1 AU2001270413A AU7041301A AU2001270413A1 AU 2001270413 A1 AU2001270413 A1 AU 2001270413A1 AU 2001270413 A AU2001270413 A AU 2001270413A AU 7041301 A AU7041301 A AU 7041301A AU 2001270413 A1 AU2001270413 A1 AU 2001270413A1
Authority
AU
Australia
Prior art keywords
improved liposomal
liposomal camptothecins
camptothecins
improved
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270413A
Inventor
Thomas D Madden
Sean C. Semple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of AU2001270413A1 publication Critical patent/AU2001270413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
AU2001270413A 2000-06-30 2001-06-29 Improved liposomal camptothecins and uses thereof Abandoned AU2001270413A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21555600P 2000-06-30 2000-06-30
US60/215,556 2000-06-30
US26461601P 2001-01-26 2001-01-26
US60/264,616 2001-01-26
PCT/CA2001/000981 WO2002002078A2 (en) 2000-06-30 2001-06-29 Improved liposomal camptothecins and uses thereof

Publications (1)

Publication Number Publication Date
AU2001270413A1 true AU2001270413A1 (en) 2002-01-14

Family

ID=26910152

Family Applications (3)

Application Number Title Priority Date Filing Date
AU7038501A Pending AU7038501A (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof
AU2001270385A Expired AU2001270385B2 (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof
AU2001270413A Abandoned AU2001270413A1 (en) 2000-06-30 2001-06-29 Improved liposomal camptothecins and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU7038501A Pending AU7038501A (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof
AU2001270385A Expired AU2001270385B2 (en) 2000-06-30 2001-06-29 Liposomal antineoplastic drugs and uses thereof

Country Status (12)

Country Link
US (7) US7244448B2 (en)
EP (2) EP1299084B1 (en)
JP (3) JP2004501955A (en)
CN (1) CN1245977C (en)
AT (2) ATE309787T1 (en)
AU (3) AU7038501A (en)
CA (2) CA2412795C (en)
DE (2) DE60115045T2 (en)
ES (1) ES2253398T3 (en)
IL (2) IL153676A0 (en)
MX (1) MXPA02012817A (en)
WO (2) WO2002002078A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
US7452550B2 (en) * 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
MXPA05001312A (en) * 2002-08-02 2005-08-03 Transave Inc Platinum aggregates and process for producing the same.
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp Stabilized topotecan liposomal composition and methods
US7915227B2 (en) * 2003-11-14 2011-03-29 Het Nederlands Kanker Instituut Pharmaceutical formulations employing short-chain sphingolipids and their use
WO2005072776A2 (en) * 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
CN1976711A (en) * 2004-03-18 2007-06-06 特兰萨维股份有限公司 Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
ES2616047T3 (en) 2004-05-03 2017-06-09 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug administration
EP1750673B1 (en) * 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2005117878A1 (en) * 2004-06-01 2005-12-15 Terumo Kabushiki Kaisha Irinotecan preparation
WO2006014035A1 (en) * 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
CA2582949A1 (en) * 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
JP4990786B2 (en) * 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション Compositions and methods for stabilizing drug liposome formulations
EP1811963A4 (en) * 2004-11-08 2010-01-06 Transave Inc Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
CN100348194C (en) * 2005-07-26 2007-11-14 康辰医药发展有限公司 Lipid formulation of nolatrexed dihydrochloride and its preparation method
CN100375621C (en) * 2005-11-04 2008-03-19 唐星 Vinorelbine liposome micro ball injection and its prepn
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
US20100093873A1 (en) * 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
JPWO2010058840A1 (en) * 2008-11-20 2012-04-19 テルモ株式会社 Drug release means from liposome and evaluation method for release
WO2011085815A1 (en) 2010-01-14 2011-07-21 Brainlab Ag Controlling a surgical navigation system
CN103442565B (en) * 2010-10-29 2016-08-10 健康研究股份有限公司 Use non-water soluble compounds new formulation and the method for the compound FL118 preparation for treatment of cancer
PL226015B1 (en) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US20190320975A1 (en) * 2011-06-03 2019-10-24 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP2714011B1 (en) * 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US10238602B2 (en) * 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10449193B2 (en) * 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
DK2892524T3 (en) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN
AU2013347990B2 (en) 2012-11-20 2018-01-18 Arbutus Biopharma Corp. Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
EA038671B1 (en) * 2013-05-30 2021-10-01 Кюрадигм Сас Method of increasing therapeutic or prophylactic efficiency of a pharmaceutical compound of interest
CA2933204C (en) 2013-12-18 2020-04-28 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
WO2015187883A1 (en) 2014-06-03 2015-12-10 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
FI3229776T3 (en) * 2014-11-25 2023-08-15 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US11318131B2 (en) * 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
MX2018001659A (en) 2015-08-20 2018-05-28 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment.
CN108495629A (en) 2015-08-21 2018-09-04 益普生生物制药有限公司 Use the method comprising liposome Irinotecan and the combination therapy to treat metastatic cancer of pancreas of oxaliplatin
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CA3038813C (en) 2016-04-27 2021-08-24 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
HUE059718T2 (en) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-phosphate analogs and oligonucleotides comprising the same
CA3040395A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
RU2734900C1 (en) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Liposomal composition and pharmaceutical composition
CA3090943A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
TWI737974B (en) * 2018-04-09 2021-09-01 美商標徑製藥公司 Dosing regimens for treatment of proliferative disorders
JP2021521279A (en) * 2018-04-11 2021-08-26 ニュー メキシコ テック ユニバーシティ リサーチ パーク コーポレーション Lipid prodrugs for use in drug delivery
EP3811931A4 (en) 2018-06-20 2021-08-04 FUJIFILM Corporation Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
WO2020071349A1 (en) 2018-10-01 2020-04-09 富士フイルム株式会社 Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
BR112021018739A2 (en) 2019-03-29 2022-05-03 Dicerna Pharmaceuticals Inc Compositions and methods for treating kras-associated diseases or disorders
BR112021021686A2 (en) 2019-05-03 2022-03-22 Dicerna Pharmaceuticals Inc Double-stranded nucleic acid inhibitor molecules with short sense strands
WO2021127641A1 (en) * 2019-12-20 2021-06-24 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
AU2021207504A1 (en) 2020-01-15 2022-08-04 Dicerna Pharmaceuticals, Inc. 4'-O-methylene phosphonate nucleic acids and analogues thereof
EP4192505A1 (en) 2020-08-04 2023-06-14 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
TW202313032A (en) 2021-05-24 2023-04-01 日商富士軟片股份有限公司 Treatment agent
WO2022250013A1 (en) 2021-05-24 2022-12-01 富士フイルム株式会社 Anti-tumor agent

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
WO1987004592A1 (en) * 1986-02-10 1987-08-13 Liposome Technology, Inc. Controlled-release liposome delivery system
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
EP0721328A4 (en) * 1993-09-27 1997-09-17 Smithkline Beecham Corp Camptothecin formulations
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
PL319511A1 (en) * 1994-10-05 1997-08-18 Glaxo Wellcome Inc Parenteral pharmaceutic compositions containing gf120918a
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
EP1489184A1 (en) * 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6110491A (en) * 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
EP1037610A4 (en) * 1997-09-16 2004-07-07 Osi Pharm Inc Liposomal camptothecin formulations
CA2346879A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
IL155291A0 (en) * 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline

Also Published As

Publication number Publication date
IL153676A0 (en) 2003-07-06
CA2412795C (en) 2012-10-02
CN1446079A (en) 2003-10-01
JP2014088444A (en) 2014-05-15
CA2412790C (en) 2012-11-06
WO2002002077A3 (en) 2002-12-12
MXPA02012817A (en) 2004-07-30
CN1245977C (en) 2006-03-22
WO2002002077A2 (en) 2002-01-10
ATE309786T1 (en) 2005-12-15
CA2412790A1 (en) 2002-01-10
DE60115045T2 (en) 2006-08-03
ES2253398T3 (en) 2006-06-01
DE60115044D1 (en) 2005-12-22
JP2012092148A (en) 2012-05-17
CA2412795A1 (en) 2002-01-10
US7060828B2 (en) 2006-06-13
AU2001270385B2 (en) 2006-05-25
US20020119990A1 (en) 2002-08-29
EP1299084B1 (en) 2005-11-16
US20020110586A1 (en) 2002-08-15
US20130136787A1 (en) 2013-05-30
US20060093662A1 (en) 2006-05-04
DE60115045D1 (en) 2005-12-22
WO2002002078A2 (en) 2002-01-10
ATE309787T1 (en) 2005-12-15
WO2002002078A3 (en) 2002-12-27
US20040170678A1 (en) 2004-09-02
AU7038501A (en) 2002-01-14
IL153676A (en) 2007-06-17
JP2004501955A (en) 2004-01-22
US7244448B2 (en) 2007-07-17
EP1299084A2 (en) 2003-04-09
US20060269594A1 (en) 2006-11-30
US20110086826A1 (en) 2011-04-14
DE60115044T2 (en) 2006-08-03
EP1299085A2 (en) 2003-04-09
EP1299085B1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
AU2001270413A1 (en) Improved liposomal camptothecins and uses thereof
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
AU2001256975A1 (en) Compositions and methods for inhibition of cancer invasion and angiogenesis
AU3652102A (en) Compounds and their uses
WO2000076933A3 (en) Water-resistant gypsum composition
WO2002008190A3 (en) Novel heteroaryl derivatives and use thereof as anti-tumour agents
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
WO2006052767A3 (en) Compositions and methods for stabilizing liposomal camptothecin formulations
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
AU2002219418A1 (en) Compositions of estrogen-cyclodextrin complexes
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2004032908A3 (en) Method of inhibiting angiogenesis
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
AU2002210425A1 (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereofas medicaments
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
WO2001097789A3 (en) Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
MXPA03005374A (en) Antitumoral carbazoles.
AU2001294062A1 (en) Method of treating aqueous compositions
WO2001068066A3 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer